Gilead agreed to acquire Ouro Medicines in a front‑loaded deal that pays roughly $1.675–1.68 billion upfront for OM336, a BCMAxCD3 T‑cell engager being developed for autoimmune disorders. Company announcements and reporting indicate early phase 1/2 data showed strong single‑cycle efficacy signals in conditions such as autoimmune hemolytic anemia and immune thrombocytopenia. Gilead will retain worldwide commercialization rights (China excluded) and has offered Galapagos a role to absorb operating assets and drive OM336 development toward registrational studies planned for 2027. The transaction structure — heavy on upfront cash with additional milestone contingencies — underscores big‑pharma urgency to own next‑generation T‑cell engagers and shifts operational responsibility for clinical development to Galapagos under a carve‑out collaboration.